Delayed response and survival from NovoTTF-100A in recurrent GBM

J. Lee Villano; Leena E. Williams; Karriem S. Watson; Nandini Ignatius; Marquess T. Wilson; Tibor Valyi-Nagy; Edward A. Michals; Herbert H. Engelhard

doi:10.1007/s12032-012-0338-1

Delayed response and survival from NovoTTF-100A in recurrent GBM

J. Lee Villano, Leena E. Williams, Karriem S. Watson, Nandini Ignatius, Marquess T. Wilson, Tibor Valyi-Nagy, Edward A. Michals, Herbert H. Engelhard

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

Original language	English
Article number	338
Journal	Medical Oncology
Volume	30
Issue number	1
DOIs	https://doi.org/10.1007/s12032-012-0338-1
State	Published - Mar 2013

Keywords

Brain tumor
Glioblastoma
Recurrent tumor
Survival
Tumor treatment fields

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12032-012-0338-1

Cite this

@article{daac761d085247dc99429b1e9410aea8,

title = "Delayed response and survival from NovoTTF-100A in recurrent GBM",

abstract = "We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.",

keywords = "Brain tumor, Glioblastoma, Recurrent tumor, Survival, Tumor treatment fields",

author = "Villano, {J. Lee} and Williams, {Leena E.} and Watson, {Karriem S.} and Nandini Ignatius and Wilson, {Marquess T.} and Tibor Valyi-Nagy and Michals, {Edward A.} and Engelhard, {Herbert H.}",

year = "2013",

month = mar,

doi = "10.1007/s12032-012-0338-1",

language = "English",

volume = "30",

number = "1",

}

TY - JOUR

T1 - Delayed response and survival from NovoTTF-100A in recurrent GBM

AU - Villano, J. Lee

AU - Williams, Leena E.

AU - Watson, Karriem S.

AU - Ignatius, Nandini

AU - Wilson, Marquess T.

AU - Valyi-Nagy, Tibor

AU - Michals, Edward A.

AU - Engelhard, Herbert H.

PY - 2013/3

Y1 - 2013/3

N2 - We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

AB - We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

KW - Brain tumor

KW - Glioblastoma

KW - Recurrent tumor

KW - Survival

KW - Tumor treatment fields

UR - http://www.scopus.com/inward/record.url?scp=84872041109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872041109&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0338-1

DO - 10.1007/s12032-012-0338-1

M3 - Article

C2 - 23307238

AN - SCOPUS:84872041109

SN - 1357-0560

VL - 30

JO - Medical Oncology

JF - Medical Oncology

IS - 1

M1 - 338

ER -

Delayed response and survival from NovoTTF-100A in recurrent GBM

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this